Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review

Key Points

• Assays of programmed death-ligand 1 (PD-L1) may enhance treatment options for non-small-cell lung cancer (NSCLC) patients, supporting future therapies.
• Evidence from various studies showed inconclusive results for nivolumab, pembrolizumab, and durvalumab in predicting therapy benefits.
• Systematic review examined different patient populations, yet encountered limitations given small sample sizes and study heterogeneity.
• Findings highlight the need for more robust data on PD-L1 assays to reliably inform treatment strategies for NSCLC patients.

Abstract